Patrick W Mantyh (Ph.D., J.D.) is a Professor of Pharmacology in the Arizona Cancer Centre at the University of Arizona, USA, he has been in this role since 2007. His interest is to understand the mechanisms that drive skeletal pain and develop new therapies that reduce pain and increase skeletal health.
He received his Ph. D. in neuroscience from the University of California, San Francisco in 1981 and completed a postdoctoral fellowship in pharmacology at the University of Cambridge in 1983.
Dr Mantyh's lab first developed a model of bone cancer pain in 1999 and then a model of bone fracture pain in 2007. These models are now used by labs around the world. More recently, his focus has been to investigate the cellular and molecular mechanisms that regulate musculoskeletal pain and bone remodelling, and to use these findings in the development of novel therapies that reduce skeletal pain and promote skeletal health and successful ageing.
Andrew S.C. Rice is a clinical academic active in clinical practice and translational research elucidating neuropathic pain. He is Professor of Pain Research at Imperial College London and Honorary Consultant in Pain Medicine at Chelsea and Westminster Hospital, London. Andrew’s research on neuropathic pain and covers both laboratory and clinical research spanning animal models, through deep profiling of patients with a view to personalised medicine, to clinical trials and evidence synthesis by meta-analysis. The emphasis is on neuropathic pain in the context of infectious diseases (HIV, Herpes Zoster, HTLV-1 and leprosy), diabetic neuropathy and peripheral nerve trauma, especially in a military context. He has published over 200 peer reviewed papers and has a citation (H) index of 55.
Beverly E. Thorn, PhD, ABPP, is Professor Emerita of Psychology at the University of Alabama, where she was on the faculty for 30 years, including serving as Director of the Clinical Psychology PhD program for 15 years and Department Chair for 5 years. She is the recipient of the 2018 Wilbert E. Fordyce Clinical Investigator Award from the American Pain Society and the 2020 Ronald D. Melzack Lecture Award from The International Association for the Study of Pain. She is a Fellow of the Society for Health Psychology (Division 38 of the American Psychological Association (APA)), the Society of Clinical Psychology (Division 12 of the APA), and the Society of Behavioral Medicine. Dr. Thorn has served on the editorial boards of several scientific journals, including Health Psychology, Pain, Journal of Pain, and European Journal of Pain. Her research has focused on investigating the important components of CBT for chronic painful conditions. Since retiring in 2016, she has remained actively involved in dissemination and implementation of CBT for chronic pain with low-income, multiply disadvantaged populations. She also consults in health care settings to help train behavioral health providers to implement CBT for pain management.
Dr Mark Alcock is a Specialist Pain Medicine Physician and Anaesthetist who works at the Queensland Children’s Hospital in Brisbane, Australia. He has been the clinical lead of the Queensland Interdisciplinary Paediatric Persistent Pain Service since 2016, overseeing a period of great change and growth in this tertiary level state-wide service since it secured recurrent funding.
Mark is a born and bred Tasmanian, and after completing university studies and anaesthetic training there he undertook fellowships at the Pain Management Unit at Barwon Health, Geelong, and the Children’s Pain Management Service at the Royal Children’s Hospital, Melbourne.
He is the immediate past chair of the Pain in Childhood Special Interest Group of the Australian Pain Society, an editor of the most recent edition of Acute Pain Management: Scientific Evidence (5th edition), an examiner for the Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists, and is an integral member of the first Project ECHO series dedicated to paediatric chronic pain, which is run through Children’s Health Queensland.
Christine Barry is a Senior Lecturer in Anatomy and Histology at Flinders University in Adelaide. She is a registered physiotherapist with 20 years clinical experience, including 10 as a Titled Member of Musculoskeletal Physiotherapy Australia, before completing her PhD in 2011 at the University of Adelaide.
Her current research focuses on plasticity of sensory neurons, especially in the female reproductive tract. She was awarded a 2019 Rebecca L Cooper Medical Research Foundation Project Grant to investigate sensory neuron activity and neuron-immune cell interactions relevant to vulvodynia.
North Queensland Persistent Pain Management Service
Dr Matthew Bryant (FANZCA, FFPMANZCA, FRACGP, FACRRM, Grad Dip Rural GP, MBBS) is Director of the North Queensland Persistent Pain Management Service. His team of 35 people (25 full time equivalent staff) provide multidisciplinary care to a population of 800 000 people, across five Hospital and Health Services, and an area of 770 000 km2. Prior to obtaining his Pain Medicine and Anaesthesia Fellowships, Matt worked as a rural GP in a number of locations across North Queensland and the Northern Territory. He is currently a Senior Lecturer at James Cook University, and a member of the Townsville Hospital Foundation Board and the ANZCA Faculty of Pain Medicine Queensland Regional Committee. His clinical and research interests include telehealth and pain management for Aboriginal and Torres Strait Islander people.
Associate Professor Suzanne Nielsen (BPharm, BPharmSc[Hons] PhD MPS) is the Deputy Director of the Monash Addiction Research Centre in Melbourne, and is a current NHMRC Career Development Fellow.She has published over 135 peer-reviewed publications, and been awarded more than AUD$10M in research funding. Her work has led to a greater understanding of prescription and over-the-counter drug-related problems, opioid dependence in people with chronic non-cancer pain, and the impact of policy change on opioid-related harms. She has been a registered pharmacist for over 20 years, with clinical experience in the treatment of substance use disorders includes in specialist drug treatment and community-based alcohol and drug treatment settings in Australia and the United Kingdom.